Allogene Therapeutics
Liz Barrett is the President and CEO of UroGen Pharma, a biotechnology company that develops and commercializes treatments for urologic and uro-oncological conditions. At UroGen, Liz spearheaded the 2020 approval of Jelmyto® for the treatment of low-grade upper tract urothelial carcinoma. She previously served as CEO of Novartis Oncology, where she managed the development and launch of the autologous CAR T therapy Kymriah® (tisagenlecleucel). Prior to her tenure at Novartis, she held several leadership positions at Pfizer, including Global President and General Manager of Oncology, and led the rollout of Ibrance®. She has also held leadership roles at Cephalon and Johnson & Johnson. Ms. Barrett currently serves on the Board of Directors of Sage Therapeutics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.